DrugPatentWatch Database Preview
Drugs in Development Information for Lumacaftor
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Lumacaftor?
Lumacaftor is an investigational drug.
There have been 34 clinical trials for Lumacaftor.
The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Cystic Fibrosis, Fibrosis, and Lung Diseases. The leading clinical trial sponsors are Vertex Pharmaceuticals Incorporated, Massachusetts General Hospital, and National Heart, Lung, and Blood Institute (NHLBI).
There are ninety-eight US patents protecting this investigational drug and nine hundred and thirty-nine international patents.
Summary for Lumacaftor
| US Patents | 98 |
| International Patents | 939 |
| US Patent Applications | 207 |
| WIPO Patent Applications | 91 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2018-10-01) |
| Vendors | 84 |
Recent Clinical Trials for Lumacaftor
| Title | Sponsor | Phase |
|---|---|---|
| Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation | Vertex Pharmaceuticals Incorporated | Phase 3 |
| Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. | Assistance Publique - Hôpitaux de Paris | N/A |
| Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240 | University of North Carolina | Early Phase 1 |
Clinical Trial Summary for Lumacaftor
Top disease conditions for Lumacaftor
Top clinical trial sponsors for Lumacaftor
US Patents for Lumacaftor
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lumacaftor | Start Trial | Compounds, compositions, and methods for increasing CFTR activity | Proteostasis Therapeutics, Inc. (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Modulators of ATP-binding cassette transporters | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-- fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxa- mide | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Compounds, compositions, and methods for increasing CFTR activity | Proteostasis Therapeutics, Inc. (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| Lumacaftor | Start Trial | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases | Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lumacaftor
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lumacaftor | Australia | 2015229117 | 2034-03-13 | Start Trial |
| Lumacaftor | Canada | 2942387 | 2034-03-13 | Start Trial |
| Lumacaftor | European Patent Office | 3116870 | 2034-03-13 | Start Trial |
| Lumacaftor | World Intellectual Property Organization (WIPO) | 2015138934 | 2034-03-13 | Start Trial |
| Lumacaftor | Australia | 2007235260 | 2026-04-07 | Start Trial |
| Lumacaftor | Brazil | PI0710965 | 2026-04-07 | Start Trial |
| Lumacaftor | Canada | 2648719 | 2026-04-07 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
